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Abstract
Background: As increasing numbers of dengue vaccines and therapeutics are in clinical development, standardized
consensus clinical endpoint definitions are urgently needed to assess the efficacy of different interventions with
respect to disease severity. We aimed to convene dengue experts representing various sectors and dengue
endemic areas to review the literature and propose clinical endpoint definitions for moderate and severe disease
based on the framework provided by the WHO 2009 classification.
Methods: The endpoints were first proposed and discussed in a structured expert consultation. After that, the
Delphi method was carried out to assess the usefulness, validity and feasibility of the standardized clinical disease
endpoints for interventional dengue research.
Results: Most respondents (> 80%) agreed there is a need for both standardized clinical endpoints and
operationalization of severe endpoints. Most respondents (67%) felt there is utility for moderate severity endpoints,
but cited challenges in their development. Hospitalization as a moderate endpoint of disease severity or measure of
public health impact was deemed to be useful by only 47% of respondents, but 89% felt it could bring about
supplemental information if carefully contextualized according to data collection setting. Over half of the
respondents favored alignment of the standard endpoints with the WHO guidelines (58%), but cautioned that the
endpoints could have ramifications for public health practice. In terms of data granularity of the endpoints, there
was a slight preference for a categorical vs numeric system (e.g. 1–10) (47% vs 34%), and 74% of respondents
suggested validating the endpoints using large prospective data sets.
Conclusion: The structured consensus-building process was successful taking into account the history of the
debate around potential endpoints for severe dengue. There is clear support for the development of standardized
endpoints for interventional clinical research and the need for subsequent validation with prospective data sets.
Challenges include the complexity of developing moderate disease research endpoints for dengue.
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Background
An increasing number of dengue vaccines and therapeu-
tics are currently in clinical development, and many vac-
cines are in advanced clinical development. The vaccine
trials, to date, have been designed using World Health
Organization (WHO) guidelines for determining efficacy
in endemic countries [1, 2], primarily focusing on pre-
vention of new infections. The WHO guidelines also
state that secondary endpoints for vaccine efficacy
should include the effect of vaccines on disease severity
and on clinical presentations, including atypical cases.
While the primary vaccine efficacy endpoints have been
well-defined, there are no published consensus clinical
trial endpoints to measure disease severity. A recently li-
censed dengue vaccine had moderate efficacy at prevent-
ing virologically-confirmed dengue symptomatic disease
but higher efficacy against severe disease [3]. Protection
against severe forms of disease has consequently been
added to the efficacy portfolio of dengue vaccines, and
each developer has crafted their own definition of severe
disease based on expert opinion and independent data
monitoring committee (IDMC) consensus [1, 4]. This lack
of standardization impedes our ability to compare results
between dengue clinical trials, and ultimately evaluate po-
tential products.
Although few clinical trials of therapeutic strategies to
treat dengue patients have been conducted, several drug
candidates are nearing evaluation in clinical trials. In
addition to the direct antiviral activity, an assessment of
the impact on disease severity will be critical for evalu-
ation of therapeutic interventions.
The WHO 2009 dengue classification defines the severe
end of the disease spectrum as i) dengue shock/respiratory
distress with fluid accumulation (plasma leakage), ii) se-
vere bleeding, or iii) severe organ dysfunction [5, 6]. This
categorization was recognized as a platform for the devel-
opment and the operationalization of standardized clinical
severe disease endpoints. While many clinicians and pub-
lic health officials welcomed the usefulness and practic-
ability of this classification for patient management [7, 8],
the need for development of clearly defined endpoints to
measure dengue disease severity for intervention trials
and pathogenesis studies has been highlighted by the re-
search community [6, 9–12].
In 2015, experts from academia, international public
health institutions, pharmaceutical industry, govern-
ment and non-government organizations convened four
times to define standardized endpoints of moderate and
severe dengue disease to facilitate interventional clinical
research. After the structured expert consultation, the
Delphi methodology was employed to refine the
proposed clinical endpoints and assess the usefulness,
validity and feasibility of these endpoints for interven-
tional dengue research.
Here, we present the processes that were used to de-
fine the endpoints, including the structured feedback
from the respondents on this project, and the plans for
their validation. The finalized definitions proposed for
moderate and severe dengue clinical endpoints and a
novel dengue illness index tool for measuring moderate
disease are reported in two separate papers.
Methods
Structured expert consultation (4 workshops)
Structured expert consensus methods have been used suc-
cessfully in Public Health, including the field of dengue re-
search [8, 13]. In January, 2015, the National Institute of
Allergy and Infectious Diseases (NIAID), part of the
National Institutes of Health, and the Partnership for
Dengue Control (PDC), convened a group of 27 experts to
develop standardized clinical trial endpoints to measure
dengue disease severity in interventional clinical trials
(Workshop 1, see Fig. 1). The group included clinicians
who follow and treat dengue patients, vaccine developers,
academic researchers, and public health specialists from
14 different countries in Asia, the Americas and Europe
(see Table 1). These dengue experts were identified via re-
ferral and selected to achieve a balanced representation of
subject matter experts from all sectors and from various
global endemic regions.
Following the framework provided by the 2009 WHO
classification, the experts were asked to select one of
three scientific working groups according to their ex-
pertise (Table 1):
1) Clinical Endpoints working group, to develop
endpoints for moderate and severe plasma leakage,
bleeding, and organ involvement (heart, liver, CNS)
2) Endpoint validation working group to develop plan
to validate endpoints; and
3) Dengue Illness Index working group, to develop a
tool to characterize the disease experienced at the
outpatient level.
Candidate clinical disease endpoints for interventional
trials were developed by the working group and dis-
cussed during several teleconferences and two
face-to-face meetings. The working groups reviewed the
literature characterizing dengue disease severity as well
as definitions established by international medical orga-
nizations, and proposed endpoints for each of the sever-
ity subcategories, including the principles of evaluation/
validation of the proposed endpoints. The criteria used
to develop the endpoints were: i) measurability, ii) repro-
ducibility/robustness, iii) practicability/readiness for im-
plementation, and iv) reference to the most recent
scientific evidence. The group also agreed that the end-
point definitions should include a moderate severity
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level - on the causal path to severe disease – in addition
to the severe disease endpoints.
Input on the draft endpoints was solicited from clinicians
in dengue endemic regions during two regional dengue
conferences (Workshop 2 at the 14th International Dengue
Course, Cuba, August 2015; Workshop 3 at the Regional
Conference of the International Research Consortium on
Dengue Risk Assessment, Management, and Surveillance -
IDAMS- regional Dengue conference, Vietnam, October
2015). During the second face-to-face consultation of the
expert panel (Workshop 4, November 2015, see Fig. 1), the
group agreed to employ the Delphi method to refine areas
Fig. 1 Workflow of workshops and Delphi. a Structured expert consultation (4 workshops). b The Delphi commenced with an invitation to
participate in the OA panel followed by the option of participating in the panel for Clinical Endpoints or the Dengue Illness Index, or both
Table 1 Scientific working group members and their affiliating country
Clinical Endpoint Development Dengue Illness Index Endpoint Validation
Bleeding Plasma Leakage Severe Organ Involvement
Lucy Luma (MYS) Bridget Willsa Laurent Thomasa (MTQ) Robert Edelmana Thomas Jaenischa
Norma de Boscha (VEN) Elsa Rojasa(COL) Kay Tomasheka Stephen Thomasa João Bosco Siqueiraa
Alex Precioso (BRA) Alexander Schmidt Alex Precioso Alex Precioso Annelies Wilder-Smith (SGP)
Alexander Schmidt (BEL) Beth Ann Coller Anna Durbin (USA) Alexander Schmidt Beth Ann Coller
Beth Ann Coller (USA) Cristina Cassetti Cristina Cassetti Catherine Laughlin (USA) Catherine Laughlin
Bridget Wills (VNM) Derek Wallace (SGP) Duane Gubler Cristina Cassetti Cristina Cassetti
Cristina Cassetti (USA) Emanuel Narvaez Emanuel Narvaez Emanuel Narvaez Derek Wallace
Duane Gubler (SGP) Hasitha Tissera (LKA) Lucy Lum Hasitha Tissera Emanuel Narvaez
Emanuel Narvaez (NIC) João Bosco Siqueira (BRA) Piyarat Suntarattiwong João Bosco Siqueira Hasitha Tissera
Kay Tomashek (USA) Kay Tomashek Stephen Thomas (USA) Kay Tomashek Maina L’Azou (FRA)
Thomas Jaenisch (DEU) Piyarat Suntarattiwong (THA) Michael Fay (USA)
Yee-Sin Leo (SGP) Robert Edelman (USA) Remy Teyssou (FRA)
Walla Dempsey (USA) Stephen Thomas
Walla Dempsey
Yee-Sin Leo
aWorking group leader
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of agreement with respect to the three working groups [14].
The results of the Clinical Endpoints and Dengue Illness
Index working groups are reported separately [15, 16].
Delphi method
The Delphi method is a structured forecasting/decision--
making tool that has successfully been applied for health
research in many areas, including infectious diseases and
global public health [17, 18]. The Delphi method creates
conditions that are favorable to a convergence of opin-
ions, while at the same time allowing moderators to
clearly discern points of dissent. It usually takes the form
of a written questionnaire and allows for anonymous
and independent consultation and argumentation,
thereby avoiding some of the drawbacks of face-to-face
confrontations both on the social level (e.g. power rela-
tions within a group) and the practical level (time con-
suming, especially with geographically dispersed
individuals) [19]. Responses are only visible to the mod-
erator(s) and not to the participants in order to avoid
self-moderation bias. The iterative nature of the consult-
ation, building on feedback of the respondents, allows
for the correction of potential bias in the initial questions,
which is the main fragility of classical (non-iterative and
non-interactive) queries. A potential problem with the
Delphi method is the creation of a bottleneck towards
convergence of opinions during the process [20, 21]. It is
therefore important to use both open and closed ques-
tions, and to take into account the whole spectrum of
opinions. The online platform used presented additional
advantages such as low respondent drop-out rates (redu-
cing effects of self-selection) and the possibility for re-
spondents to revisit, complement or modify their answers
during each round (generating more data). [22]
The Delphi query was subdivided into three panels: an
Overall Approach (OA) Panel, a Clinical Endpoints Panel,
and a Dengue Illness Index Panel (Fig. 1). Here we con-
centrate on the OA panel. The Delphi process was con-
ducted online using the MESYDEL platform [23]
developed by the Spiral Research Center at the University
of Liège (Belgium). Three rounds of Delphi queries were
launched and analyzed between May and August 2016.
Questions were designed by the project organizers in close
collaboration with the Spiral Research Center and were
predominantly open-ended for the OA panel, allowing
participants to raise additional elements, suggestions and
opinions. Respondents were also encouraged to explain
their choice for closed-ended and multiple choice ques-
tions. A subsequent round mainly focused on ambiguities
or disagreement in the previous round, clarifying areas of
disagreement and fostering more consensus on ap-
proaching the issue differently according to the partici-
pants’ input. A third round gauged participants’ appraisal
of both the content and form of the Delphi.
The key topic areas covered in the OA panel of the
consultation were:
1. Need for standardized clinical endpoints &
operationalization of severe endpoints
2. Utility of moderate severity endpoints
3. Hospitalization as a moderate endpoint
4. Potential ramifications for public health practice
5. Granularity of endpoints
6. Validation of endpoints
Quantitative data for closed questions was tabulated
using software analysis. Written responses were analyzed
using a software ‘tagging’ approach. In this approach, the
software selected parts of text from individual respon-
dents and then grouped the text into function areas of a
shared concern (although opinions might differ), a spe-
cific theme or subject that occurred regularly through
various responses, or, on the contrary, a minority view-
point that brought in new and different information.
This approach resulted in a group of tags, indicating a
set of relevant issues, for each question in each round of
the Delphi. Grouped and tabulated under tags, the re-
sponses to each question were analyzed a second time to
further develop the specific issues and check the pertin-
ence of the tags themselves. The issues and themes thus
identified served to elaborate new questions, or to mod-
ify existing questions in the next round of the Delphi.
Particular attention was paid to areas of disagreement.
Results
Demographics and participation rates
Sixty-four individuals (including the 27 working group
members), representing a total of 17 countries, were in-
vited to the OA Panel. Thirty-nine of them (from 16
countries) agreed to participate (Fig. 1) and thirty-eight
actively responded beginning with round 1 (Table 2).
Respondents then self-selected to participate in either or
both of the other two panels: the Clinical Endpoints
Panel and the Dengue Illness Index Panel (Fig. 1).
The participants of the OA panel identified themselves
as practicing in the following sectors: 50% from aca-
demia, 32% from industry, 26% from public health prac-
tice, 29% from clinical practice. These percentages add
to more than 100%, as the respondents could select sev-
eral options. The participation rate was 97% in the first
round with a 74% completion rate of the questionnaire.
In the second round, the participation rate was slightly
lower with72%.
Need for standardized clinical endpoints and
operationalization
Round 1 of the Delphi OA panel indicated an agreement
on the utility of clinical endpoints for interventional
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Table 2 Delphi consensus approach – results of the overall approach round 1 and 2
Questions Round 1 (N = 38)* Round 2 (N = 28)*
Yes No Yes No
Need for standardized clinical endpoints and operationalization No. (%) No. (%) No. (%) No. (%)
1.1.1 Should specific clinical endpoints be defined for dengue interventional trials? 32 (84) 0 (0)
1.1.2 If not, briefly explain why not.
1.1.3 Do you think we also need clinical endpoint definitions for pathogenesis research? 31 (82) 1 (3)
1.2.1 Do you think operationalization of severe dengue endpoints is necessary for interventional trials? 31 (82) 0 (0)
2.1.1 Please let us know what information you consider essential to further characterize these endpoints.
Ideal time to collect clinical samples and clinical information 26 (93) 2 (7)
Details on how to measure endpoints (specific assays, instrumentation, etc) 25 (89) 3 (11)
Chart with endpoints and checkboxes 18 (64) 10 (36)
Different instructions for children and adults 17 (61) 11 (39)
2.1.2 Could you please provide additional suggestions/ideas?
Moderate severity endpoints
1.3.1 Do you think there should be a moderate disease severity category? 29 (76) 3 (11)
1.3.2 Briefly explain why or why not.
2.2.1 The goal of this project is to develop endpoints for dengue intervention clinical research.
These endpoints are meant for interventional clinical research only and we were never
meant to modify or substitute the 2009 WHO classification. Do you think moderate
endpoints should be proposed based on the best scientific evidence available so far
and validated afterward utilizing ongoing or new studies?
27 (96) 1 (4)
2.2.2 Please explain your answer.
Hospitalization as moderate endpoint
1.4.1 Should prevention of hospitalization be the endpoints for dengue interventional trials? 14 (37) 18 (47)
1.4.2 Briefly explain why or why not.
2.4.1 Do you think that information on hospitalization should be collected during interventional
clinical trials and used in conjunction with other endpoints of disease severity?
25 (89) 1 (4)
2.4.2 What is the main reason why information on hospitalization should be collected during
an interventional trial?
2.4.3 Please explain your answers.
Potential ramifications for public health practice
1.5.1 Do you think the severe/moderate dengue severity endpoints for research purposes should
be based on/aligned with the dengue classification for severity as set forth WHO 2009?
22 (58) 10 (26)
1.5.2 Do you think moderate disease severity endpoint definitions will impact public health practices? 19 (50) 12 (32)
1.5.3 Briefly explain why or why not.
2.3.1 Can you please elaborate on why do you think the severe/moderate endpoints should
or should not be based on the 2009 WHO dengue classification?
2.3.2 Can you suggest ways to minimize the potential impact of these endpoints for research
on public health practices?
Granularity of endpoints
1.6.1 To measure disease severity in interventional research, do you think that a categorical
system (e.g. moderate vs. severe) or a numerical point system (e.g. 1–10) would be better?
18 (47) 13 (34)
1.6.2 Briefly explain your selection.
2.5.1 Should a categorical system be developed first? 20 (71) 6 (21)
2.5.2 Do you think it’s a good idea to develop a numerical system in parallel and that
relative weight / importance / comparability be assessed prospectively?
20 (71) 7 (25)
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research (84%), for pathogenesis research (82%) and
on the need to operationalize these endpoints (82%)
(Table 2). In round 2, participants were asked which
information they thought was essential to further
characterize these endpoints. Information considered
to be essential included: i) ideal time to collect clinical
samples and information, (93% of the participants); ii) de-
tails on how to measure endpoints (e.g. specific assays, in-
strumentation; which was indicated by 89%; iii) chart with
endpoints and checkboxes (64%); and iv) different instruc-
tions for children and adults (61%).
Moderate severity endpoints
Seventy-six percent of the respondents agreed that a mod-
erate disease category would be desirable as severe disease
is considered rare and requires large sample sizes to meas-
ure during interventional clinical trials. In addition, de-
fined moderate disease endpoints would allow a better
characterization of the disease spectrum, and if properly
defined, would indicate a stage in the progression of the
disease and could have predictive value.
Although nearly all participants were in support of de-
veloping moderate endpoints, many pointed out the in-
herent challenges including the fact that they could not
be statistically separated in a previous effort [6].
The respondents assigned different background ratio-
nales to the need of moderate disease severity endpoints,
namely i) the importance of detecting small changes (as
these changes may be incremental); ii) the rare occurrence
of severe forms of dengue in clinical studies; and iii) the
need to better characterize the disease spectrum of den-
gue. In addition, some respondents went beyond the re-
search context mentioning iv) patient management and
disease burden. In round 2, a majority of participants
(96%) confirmed that moderate endpoints should be pro-
posed based on the best scientific evidence available,
which includes validation by ongoing or new studies. In
addition, the need for prospective studies to validate the
endpoints was spontaneously raised by some respondents.
Hospitalization as moderate disease endpoint
In the first round, a slight majority (47% versus 37%) felt
hospitalization would not be a meaningful endpoint for
dengue interventional trials, primarily due to the hetero-
geneity of hospitalization polices among countries and
regions, and between private and public hospitals within
a country. Although the information hospitalization is
relatively easy to ascertain (and likely be recorded re-
gardless), the heterogeneity would still present a signifi-
cant confounder for any direct comparisons.
However, 43% of respondents who elaborated on their
response (see Table 2 question 1.4.2) argued that
hospitalization could be one endpoint among others. It
was also mentioned that despite the inherent heterogen-
eity, the hospitalization rate would still be a good proxy
reflecting health expenditure. Yet other respondents im-
plicitly questioned the pertinence of hospitalization as a
measure for public health impact, next to its impracti-
cality as a clinical endpoint according to the respon-
dents. These opinions stand in contrast to those who
think that hospitalization is an important endpoint from
a public health perspective. In round 2, the majority of
respondents agreed (89%) that data on hospitalization
should be collected during interventional trials and used
in conjunction with other endpoints of disease severity.
When prompted to identify why such information
should be collected, the main response categories were
i) to measure the impact of an intervention on the
health system (46%); ii) that hospitalization reflects dis-
ease severity and could be used as a proxy for moderate
disease severity (35%).
In summary, hospitalization may be of limited use either
to measure public health impact or as a proxy for disease
severity, but questions around hospitalization stimulated
numerous concerns. A conclusion that might garner ap-
proval by all is that hospitalization can bring additional in-
formation provided that a) it is used in conjunction with
other variables; and b) it is carefully contextualized ac-
cording to the time and place where it is collected.
Potential ramifications for public health practice
Questions revolved around the alignment of severe/
moderate dengue severity endpoints with the WHO
2009 dengue classification (Table 2, question 1.5.1) and
around the concern that moderate disease severity end-
point definitions might in turn impact public health
Table 2 Delphi consensus approach – results of the overall approach round 1 and 2 (Continued)
Questions Round 1 (N = 38)* Round 2 (N = 28)*
Yes No Yes No
Validation of endpoints
1.7.1 Should suggested endpoints be validated with large prospective data sets? 28 (74) 3 (8)
1.7.2 If not, briefly explain why not.
*Note: the total number of participants who agreed and disagreed to a specific question may not equal the column total of all active participants for that round
because of non-responders, that is, participants were not obliged to respond to a specific question to proceed to the next question. The percentages in
parentheses were calculated based on the number of active respondents in each round, not on the actual number of respondents for each individual question.
For this reason, the percentages of ‘yes’ and ‘no’ for each question do not necessarily add up to 100%
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practices when implemented (1.5.2).The later question
was accompanied by an open question (1.5.3) in which
the participants were asked to elaborate on their answer.
In round 1, 58% were in favor of an alignment with
the WHO guidelines. The second round included an
open question (Table 2, question 2.3.1) asking the partic-
ipants to explain in more detail. Fifty-seven percent of
the respondents were in favor of an alignment with the
WHO guidelines and pointed out that the WHO classifi-
cation had clinical utility and that it was important to
maintain a historical and practical continuity. Several
also pointed out that the 2009 WHO classification was a
good platform for further adaptation and refinement.
The remaining respondents (n = 5) did not position
themselves clearly, indicating that the feasibility of align-
ment with WHO remains to be seen in practice. When
the respondents were analyzed for their sector of activ-
ity, nearly 82% from the public health sector and 70%
from the clinical sector favored alignment with the
current WHO classification.
The development of moderate endpoints generated
the most divergent discussion with respect to possible
ramifications for public health practice. About half of
the participants (50%) thought that ramifications will
impact public health practice (32% declined). Some re-
spondents were unsure about the precise meaning of
‘public health practice,’ whether it referred to patient tri-
age, treatment, or to hospitalization practices. This also
revealed different visions about the objective and scope
of the moderate disease endpoints: while for some re-
spondents a moderate category would help to prioritize
who should be hospitalized, others feared that adding
moderate endpoints would engender confusion with re-
spect to the current WHO guidelines. At the same time,
many respondents thought that the moderate category
will have no public health impact, irrespective of WHO
alignment.
Round 2 concentrated on what should be done to
minimize the public health impact of the research end-
points. Here two main groups of answers stood out.
About 25% of the 19 participants who responded con-
ceptualized this as a communication issue – highlighting
the need to clearly explain the uses and objectives of
these moderate severity endpoints. About 25% stated
that the question was unclear or irrelevant. The com-
ments also exemplified paradoxical expectations with re-
spect to moderate disease endpoints: that while
moderate classification was being developed for research
purposes, there were concerns about possible public
health practice consequences in terms of hospitalization
and economic burden.
In summary, the main concern raised with respect to
the public health ramifications was the possible confu-
sion that might be created in disease endemic countries
by classifications and definitions of severe disease cur-
rently used for clinical management versus new clinical
endpoints developed for research purposes. Yet, other
respondents were confident that local diagnosis and
management guidelines were well established and would
not be impacted by the dissemination of new research
endpoints as long as the purpose of the new endpoints
was clearly communicated.
Granularity of endpoints
The degree of granularity to be achieved by the end-
points was a matter of discussion. When asked if the
endpoints for clinical research should follow a categor-
ical system (e.g. moderate vs. severe) or a numerical
point system (e.g. 1–10), 47% preferred a categorical sys-
tem and 34% preferred a numerical system. A categorical
system was perceived as a first priority in the second
round (71% in favor), with the option to develop a nu-
merical system once more data are available (data on the
relative weights/importance of the different manifesta-
tions in subcategories of severe/moderate disease). Rea-
sons in favor of a categorical system included the ease in
use and communication of such a system and its greater
robustness with regard to heterogeneity. The experts felt
that a numerical system implied a greater precision,
which is currently not underpinned by the available data.
In addition, a numerical system implied linearity of in-
creasing severity, and that severity with the same num-
ber score is comparable between severity categories (i.e.
between leakage and a given organ dysfunction).
Proponents of a numerical system liked the increased
accuracy. With a numerical system, average severity
could be compared between groups, and other features
like duration of symptoms could easily be associated and
analyzed as well. The argument also takes up the need
for more granularity in the endpoints.
Validation of endpoints
A majority (74%) agreed that the suggested endpoints
should be validated using large prospective data sets. The
way forward for validation of the endpoints was discussed
in the structured expert consultation as well as in the
Delphi. There was a broad agreement that the candidate
clinical endpoints [15] should be validated using available
data sets as well as prospectively collected data sets. Major
criteria for validation of these endpoints are i) accuracy to
reflect severe/moderate disease, ii) robustness in different
environments, and iii) practical considerations.
Satisfaction with Delphi
Ninety-four percent of the 17 active respondents
expressed satisfaction that their input was taken into ac-
count and that the feedback provided throughout the
process was sufficient and addressed all relevant issues.
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One comment reflected a desire for feedback to reflect
the representativeness of the Delphi panels, while other
comments expressed value in the Delphi exercise to map
out certain contentious positions.
Discussion
The results of the structured expert consultation and the
Delphi approach clearly indicate support for the need of
standardized clinical endpoints for interventional re-
search and for the development of specific guidance on
what data to collect, including the type of specimens,
medical investigations, and even suggested time points
for collection. A large majority of participants was also
in favor of developing moderate endpoints, in spite of
the fact that earlier attempts to quantify evidence-based
moderate endpoints were not successful [6]. The slight
majority of participants felt that these endpoints for re-
search should be aligned with the 2009 WHO classifica-
tion to leverage the existing body of knowledge and for
continuity and consistency.
A slight majority of participants felt that hospitalization
would not constitute a standalone endpoint for dengue
interventional trials (except for its significance in resource
expenditure), since the criteria for hospitalization vary
widely within regions. However, most participants felt that
hospitalization was a valuable piece of information that
should be captured and considered together with other
clinical outcomes to get a more complete picture of the ef-
fect of interventions on a patient outcome.
Some of the participants expressed concerns that the
introduction of moderate endpoints for interventional
research might have an impact on public health practice.
A slight majority of respondents agreed with this pos-
ition and pointed out that a moderate category might be
adopted by physicians to discern between patients that
require hospitalization or not. A slight minority was not
concerned by possible impacts because the effort of end-
point development is clearly for interventional research
trials use only and would simply not be feasible in
routine (non-research) clinical settings in most
dengue-endemic countries. The clinical endpoints gener-
ated here are designed to provide guidance for interven-
tional clinical research only and are not meant to modify
or substitute existing classification systems or influence
clinical management decisions. A concerted effort will
be made by the organizers of this project to clearly com-
municate that these endpoints are meant exclusively to
facilitate interventional research studies.
During this Delphi approach, respondents naturally
brought in matters of clinical management, disease bur-
den and hospitalization when elaborating their vision on
both moderate/severe disease research endpoints and
the WHO 2009 guidelines. Thus, the disease categories/
endpoints that this Delphi addressed were put into a
relationship with clinical practice beyond the scope of
research and interventional trials alone. Consistent with
the purpose of this consultation, some participants
(Table 2 question 1.5.1,) argued that a separation be-
tween the research context and the clinical context is
important for the elaboration and use of the endpoints
suggested by this Delphi.
Regarding granularity, a slight majority preferred a cat-
egorical system (e.g. moderate versus severe) to a nu-
merical scoring system (e.g. 1–10) since it would be
easier to use in interventional research trials, and the
data currently available are not sufficiently robust to
support a numerical system. As additional data on dis-
ease severity are collected, a numerical scoring system
might be subsequently developed to improve precision
in the measurement of clinical outcomes during a trial.
A large majority agreed that the proposed endpoints
should be validated using large prospective data sets.
The Delphi queried a broad segment of experts from
various geographical regions with heterogeneous profes-
sional backgrounds related to dengue. As indicated earl-
ier, the results do not allow correlating specific issues or
opinions with the geographical background of the
respondents. It should be noted, however, that some of
the answers do suggest that the resources available in
low-income countries may have an impact on the feasibil-
ity and comparability of the endpoints to be developed
and other information (such as hospitalization) to be gath-
ered. Political and economic factors, such as the role and
presence of private hospitals with respect to public hospi-
tals, may also influence how dengue is charted and sever-
ity is evaluated in certain geographical areas. Knowledge
of the role of such factors, and a view on their distribution
across geographical areas, will contribute to the effort of
developing comparable standardized endpoints.
The next step in this process is to begin a validation
process for the utility of the consensus endpoints. In the
absence of a formal ‘gold standard’, the validation of accur-
acy is the most challenging task. In the past, the validation
of accuracy has been carried out using medical interven-
tions (e.g. ICU level monitoring and IV fluid therapy, blood
transfusion, shock resuscitation) as reference categories [6].
The validation of the accuracy of moderate endpoints for
dengue severity needs to take into account the causal path
to the corresponding severe disease endpoint (e.g. fluid
accumulation leading to severe vascular leakage).
The evaluation of robustness includes the frequency
distribution of the abnormal variables included in the
outcome definitions, stratified among other factors by
geography and age (group). Large variability of the fre-
quency distributions would indicate underlying factors
that influence abnormal values and therefore the com-
parability of data between different settings. In addition,
the repeatability of the measurements needs to be
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assessed, especially for variables that include a subjective
component of assessment.
Practical considerations include the quality and avail-
ability of the variables required for the endpoint defini-
tions in different data sets. Here we suggest distinguishing
between ‘minimal data sets’ and optimal or full data sets
for endpoint definitions. The minimal data sets would en-
tail the most robust and readily available variables that are
necessary for endpoint definition. Certain endpoints might
not even be classifiable with a minimal data set (e.g. for se-
vere/moderate cardiac involvement). The most important
endpoints (e.g. the endpoints responsible for the majority
of severe disease in dengue) should at least be reflected in
the minimal data set.
In order to evaluate this strategy, we first suggest inves-
tigating existing prospectively collected data sets with re-
gard to the candidate endpoints definitions. In addition to
the categories mentioned above, this would also allow the
identification of potential gaps in the data sets and lead to-
wards clear requirements for future prospective data sets.
Conclusions
The results of this iterative process indicated a clear need
for standardized clinical endpoints for dengue interven-
tional research. Challenges that were identified include: i)
the complexity of developing moderate disease research
endpoints for dengue; ii) the potential influence of clinical
endpoints for interventional research on clinical practice;
iii) communication of the purpose and proper use of these
endpoints to clinical and public health officials; iv) the
need to evaluate the suggested candidate endpoints with
well-designed prospective studies.
For this project, experts from academia, industry and
clinical practice from several dengue endemic countries
were invited to address an important gap in vaccine and
therapeutic research. Their continued efforts over 2 years
resulted in the development of candidate clinical end-
points for moderate and severe dengue disease that are
meant to facilitate the design of interventional clinical tri-
als. While these endpoints will need to be validated with
existing or future prospective data sets, this presents a sig-
nificant step forward towards the standardization and
harmonization of clinical trials for dengue interventions.
The structured process, utilizing an expert panel and the
Delphi method, proved useful for reaching agreement and
documenting areas where further discussion is needed.
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